All In MedTech

Device Trial Radar · NCT05837455

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

NeoTAILOR: A Phase II Biomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

81

Planned (sponsor's estimate)

Start

May 30, 2024

Primary completion

Nov 30, 2027

Study completion Nov 30, 2027

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Swim Across America; The Foundation for Barnes-Jewish Hospital
First posted
May 1, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to utilize a novel biomarker-driven approach to guide neoadjuvant treatment selection. It is the hypothesis that this will improve clinical response for postmenopausal women with clinical stage II/III ER-positive, HER2-negative breast cancer and identify those who may not require neoadjuvant chemotherapy, with a primary focus on outcomes in Black patients.

Conditions

  • Breast Cancer
  • Cancer of the Breast

Interventions

  • VENTANA MIB-1 Ki67 assayDevice

    Ki67 scoring determination (standard of care) utilizing the Ki67 MIB-1 assay (clone 30-9) (VENTANA) will be performed at baseline, Week 4 (+/- 14 days - high-risk group only), and at time of surgery in accordance with the International Ki67 in Breast Cancer Working Group guidelines.

  • Oncotype DX® Recurrence ScoreDevice

    Oncotype DX® Recurrence Score (RS) testing - assessing expression of 21 genes including 16 cancer-related genes and 5 reference genes - will be performed as standard of care in a central laboratory (Exact Sciences) on RNA extracted from formalin-fixed paraffin-embedded core-biopsy samples.

  • PAM50-based Prosigna breast cancer gene signature assayDevice

    This PAM50-based Prosigna breast cancer gene signature assay for intrinsic molecular subtype determination will be performed on formalin-fixed, paraffin-embedded (FFPE) core-biopsy samples.

  • AnastrozoleDrug

    Standard of care. All patients must start on anastrozole at time of enrollment but may switch to another aromatase inhibitor (letrozole or exemestane) due to toxicity or financial/other concerns at discretion of investigator after a discussion with the PI. Every effort to minimize interruption of aromatase inhibitor (AI) therapy is recommended.

  • Combination anthracycline and/or taxane based treatmentDrug

    Standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) by breast MRI in the combined low-risk plus high-risk endocrine-sensitive groups (pooled endocrine therapy-responders)Time frame: Through completion of treatment (estimated to be 6 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.